Review



champion ada  (Abbott Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Abbott Laboratories champion ada
    Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.
    Champion Ada, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/champion+ada/champion+ada/pmc06328353-160-5-4
    Average 90 stars, based on 1 article reviews
    champion ada - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences."

    Article Title: Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

    Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

    doi: 10.1111/jdv.15174

    Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.
    Figure Legend Snippet: Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.

    Techniques Used: Comparison, Immunopeptidomics

    Characteristics of the Non-Inferiority Randomized, Controlled Trials with an Active Comparator.
    Figure Legend Snippet: Characteristics of the Non-Inferiority Randomized, Controlled Trials with an Active Comparator.

    Techniques Used:

    Related Articles

    Comparison:

    Article Title: Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.
    Article Snippet: NCT00235820 43 , 44 Abbott (2008) CHAMPION ADA MTX PBO 250 (2:2:1) 271 (108/110/53) PASI75 16 62% ADA vs. 60% MTX 95 −20 0.80 ITT, PP No 1 NCT01358578 45 Novartis (2013) FIXTURE c SEC (AIN457) – 150mg & 300mg ETA PBO 1264 (1:1:1:1) 1305 (327/323/323/324) PASI75 12 55% SEC vs. 50% ETA 98.75 −10 0.90 ITT Yes, prior studies 1 NCT01241591 46 Pfizer (2015) Tofacitinib vs. ETA or PBO Tofacitinib – 5mg & 10mg ETA PBO 1101 (329/330/335/107) PASI75 12 39.5% 5mg vs. 63.6% 10mg vs. 58.8% ETA vs. 5.6% PBO 95 −15 0.95 ITT No 1 NCT01726933 47 Almirall (2015) BRIDGE LAS41008 (DMF) Fumaderm® (LASW1835) PBO 690 (2:2:1) 671 (267/273/131) PASI75 16 50% DMF vs. 35% Fumaderm® 95 −15 0.9 ITT, PP No 1 NCT02561806 48 Eli Lilly and Co. (2017) IXORA-S d Izekizumab UST - 300 (1:1) 302 (166/136) PASI90 12 70% IXE vs. 43% UST 95 −12.6 >0.95 ITT Yes, “in-house data” 1 Table2B.

    Immunopeptidomics:

    Article Title: Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.
    Article Snippet: NCT00235820 43 , 44 Abbott (2008) CHAMPION ADA MTX PBO 250 (2:2:1) 271 (108/110/53) PASI75 16 62% ADA vs. 60% MTX 95 −20 0.80 ITT, PP No 1 NCT01358578 45 Novartis (2013) FIXTURE c SEC (AIN457) – 150mg & 300mg ETA PBO 1264 (1:1:1:1) 1305 (327/323/323/324) PASI75 12 55% SEC vs. 50% ETA 98.75 −10 0.90 ITT Yes, prior studies 1 NCT01241591 46 Pfizer (2015) Tofacitinib vs. ETA or PBO Tofacitinib – 5mg & 10mg ETA PBO 1101 (329/330/335/107) PASI75 12 39.5% 5mg vs. 63.6% 10mg vs. 58.8% ETA vs. 5.6% PBO 95 −15 0.95 ITT No 1 NCT01726933 47 Almirall (2015) BRIDGE LAS41008 (DMF) Fumaderm® (LASW1835) PBO 690 (2:2:1) 671 (267/273/131) PASI75 16 50% DMF vs. 35% Fumaderm® 95 −15 0.9 ITT, PP No 1 NCT02561806 48 Eli Lilly and Co. (2017) IXORA-S d Izekizumab UST - 300 (1:1) 302 (166/136) PASI90 12 70% IXE vs. 43% UST 95 −12.6 >0.95 ITT Yes, “in-house data” 1 Table2B.



    Similar Products

    champion ada  (Abbott Laboratories)
    90
    Abbott Laboratories champion ada
    Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.
    Champion Ada, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/champion+ada/champion+ada/pmc06328353-160-5-4
    Average 90 stars, based on 1 article reviews
    champion ada - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.

    Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

    Article Title: Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

    doi: 10.1111/jdv.15174

    Figure Lengend Snippet: Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs.

    Article Snippet: NCT00235820 43 , 44 Abbott (2008) CHAMPION ADA MTX PBO 250 (2:2:1) 271 (108/110/53) PASI75 16 62% ADA vs. 60% MTX 95 −20 0.80 ITT, PP No 1 NCT01358578 45 Novartis (2013) FIXTURE c SEC (AIN457) – 150mg & 300mg ETA PBO 1264 (1:1:1:1) 1305 (327/323/323/324) PASI75 12 55% SEC vs. 50% ETA 98.75 −10 0.90 ITT Yes, prior studies 1 NCT01241591 46 Pfizer (2015) Tofacitinib vs. ETA or PBO Tofacitinib – 5mg & 10mg ETA PBO 1101 (329/330/335/107) PASI75 12 39.5% 5mg vs. 63.6% 10mg vs. 58.8% ETA vs. 5.6% PBO 95 −15 0.95 ITT No 1 NCT01726933 47 Almirall (2015) BRIDGE LAS41008 (DMF) Fumaderm® (LASW1835) PBO 690 (2:2:1) 671 (267/273/131) PASI75 16 50% DMF vs. 35% Fumaderm® 95 −15 0.9 ITT, PP No 1 NCT02561806 48 Eli Lilly and Co. (2017) IXORA-S d Izekizumab UST - 300 (1:1) 302 (166/136) PASI90 12 70% IXE vs. 43% UST 95 −12.6 >0.95 ITT Yes, “in-house data” 1 Table2B.

    Techniques: Comparison, Immunopeptidomics

    Characteristics of the Non-Inferiority Randomized, Controlled Trials with an Active Comparator.

    Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

    Article Title: Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

    doi: 10.1111/jdv.15174

    Figure Lengend Snippet: Characteristics of the Non-Inferiority Randomized, Controlled Trials with an Active Comparator.

    Article Snippet: NCT00235820 43 , 44 Abbott (2008) CHAMPION ADA MTX PBO 250 (2:2:1) 271 (108/110/53) PASI75 16 62% ADA vs. 60% MTX 95 −20 0.80 ITT, PP No 1 NCT01358578 45 Novartis (2013) FIXTURE c SEC (AIN457) – 150mg & 300mg ETA PBO 1264 (1:1:1:1) 1305 (327/323/323/324) PASI75 12 55% SEC vs. 50% ETA 98.75 −10 0.90 ITT Yes, prior studies 1 NCT01241591 46 Pfizer (2015) Tofacitinib vs. ETA or PBO Tofacitinib – 5mg & 10mg ETA PBO 1101 (329/330/335/107) PASI75 12 39.5% 5mg vs. 63.6% 10mg vs. 58.8% ETA vs. 5.6% PBO 95 −15 0.95 ITT No 1 NCT01726933 47 Almirall (2015) BRIDGE LAS41008 (DMF) Fumaderm® (LASW1835) PBO 690 (2:2:1) 671 (267/273/131) PASI75 16 50% DMF vs. 35% Fumaderm® 95 −15 0.9 ITT, PP No 1 NCT02561806 48 Eli Lilly and Co. (2017) IXORA-S d Izekizumab UST - 300 (1:1) 302 (166/136) PASI90 12 70% IXE vs. 43% UST 95 −12.6 >0.95 ITT Yes, “in-house data” 1 Table2B.

    Techniques: